Downloads
Abstract
Background: Gastric cancer is one of the most common cancers in Vietnam. This study aimed to assess the outcome of recurrent/metastatic gastric cancer patients treated with paclitaxel after first - line therapy at K hospital.
Methods: This was a descriptive, retrospective study conducted on 33 patients diagnosed with recurrent/metastatic gastric cancer at K Hospital from January 2016 to April 2020.
Results: Objective response rate was 21.2%; clinical benefit rate was 57.6%; no association was found between objective response rate and patient characteristics. Median progression-free survival time was 3.3 month. Adverse events were mostly not serious and could be managed well, the most common were anemia (41.8% grade 1 and 8.8% grade 2), neutropenia (35.3% grade 1 and 17.1% grade 2), anorexia (24.7% grade 1 and 12.9% grade 2) and peripheral neurotoxicity (22.3% grade 1 and 2.9% grade 2). The only grade 3 toxicity was neutropenia (6.5%).
Conclusions: Treatment of recurrent/metastatic gastric cancer after first-line therapy with paclitaxel at K hospital achieved positive results, most of the adverse events were at grade 1 and 2 and could be managed well.
References
Đức NB and Phong ĐN, Dịch tễ học bệnh ung thư: Lịch sử hình thành và tiến triển bệnh ung thư. 2008: Nhà xuất bản Y học.
Casaretto L, Sousa PL, and Mari JJ. Chemotherapy versus support cancer treatment in advanced gastric cancer: a meta-analysis. Braz J Med Biol Res. 2006. 39(4): 431-40.
Kang JH, Lee SI, Lim DH, Park KW, Oh SY, Kwon HC, et al. Salvage chemotherapy for pretreated gastric cancer: a randomized phase III trial comparing chemotherapy plus best supportive care with best supportive care alone. J Clin Oncol. 2012. 30(13): 1513-8.
Thuss-Patience PC, Kretzschmar A, Bichev D, Deist T, Hinke A, Breithaupt K, et al. Survival advantage for irinotecan versus best supportive care as second-line chemotherapy in gastric cancer--a randomised phase III study of the Arbeitsgemeinschaft Internistische Onkologie (AIO). Eur J Cancer. 2011. 47(15): 2306-14.
Glimelius B, Ekstrom K, Hoffman K, Graf W, Sjoden PO, Haglund U, et al. Randomized comparison between chemotherapy plus best supportive care with best supportive care in advanced gastric cancer. Ann Oncol. 1997. 8(2): 163-8.
Cascinu S, Graziano F, Cardarelli N, Marcellini M, Giordani P, Menichetti ET, et al. Phase II study of paclitaxel in pretreated advanced gastric cancer. Anticancer Drugs. 1998. 9(4): 307-10.
Yamaguchi K, Tada M, Horikoshi N, Otani T, Takiuchi H, Saitoh S, et al. Phase II study of paclitaxel with 3-h infusion in patients with advanced gastric cancer. Gastric Cancer. 2002. 5(2): 90-5.
Yamada Y, Shirao K, Ohtsu A, Boku N, Hyodo I, Saitoh H, et al. Phase II trial of paclitaxel by three-hour infusion for advanced gastric cancer with short premedication for prophylaxis against paclitaxel-associated hypersensitivity reactions. Ann Oncol. 2001. 12(8): 1133-7.
Hironaka S, Ueda S, Yasui H, Nishina T, Tsuda M, Tsumura T, et al. Randomized, open-label, phase III study comparing irinotecan with paclitaxel in patients with advanced gastric cancer without severe peritoneal metastasis after failure of prior combination chemotherapy using fluoropyrimidine plus platinum: WJOG 4007 trial. J Clin Oncol. 2013. 31(35): 4438-44.
Ajani JA, Fodor MB, Tjulandin SA, Moiseyenko VM, Chao Y, Cabral Filho S, et al. Phase II multi-institutional randomized trial of docetaxel plus cisplatin with or without fluorouracil in patients with untreated, advanced gastric, or gastroesophageal adenocarcinoma. J Clin Oncol. 2005. 23(24): 5660-7.
Toản VQ, Đánh giá kết quả điều trị ung thư dạ dày giai đoạn IIB-III (T4, N0-3, M0) bằng hóa chất bổ trợ EOX sau phẫu thuật tại bệnh viện K. 2017, Trường Đại học Y Hà Nội.
Vượng NT, Đánh giá hiệu quả phác đồ XELOX trong điều trị bổ trợ ung thư dạ dày. 2013, Trường Đại học Y Hà Nội.
Thế VV, Đánh giá kết quả hoá trị phác đồ DocetaxelCisplatin bệnh ung thư dạ dày giai đoạn muộn tại Bệnh viện K. 2015, Trường Đại học Y Hà Nội.
Hạnh TN, Đánh giá kết quả hóa trị liệu phác đồ EOX cho ung thư dạ dày giai đoạn muộn không còn khả năng phẫu thuật triệt căn. 2012, Trường Đại học Y Hà Nội.
Anh PM and Thọ LT. Nghiên cứu đặc điểm giải phẫu bệnh ung thư dạ dày điều trị tại bệnh viện Ung bướu Hà Nội 2010-2012. Tạp chí Y học thực hành. 2012: 112-115.
Ohtsu A, Boku N, Tamura F, Muro K, Shimada Y, Saigenji K, et al. An early phase II study of a 3-hour infusion of paclitaxel for advanced gastric cancer. Am J Clin Oncol. 1998. 21(4): 416-9.
Wilke H, Muro K, Van Cutsem E, Oh SC, Bodoky G, Shimada Y, et al. Ramucirumab plus paclitaxel versus placebo plus paclitaxel in patients with previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (RAINBOW): a double-blind, randomised phase 3 trial. Lancet Oncol. 2014. 15(11): 1224-35.
Feldweg AM, Lee CW, Matulonis UA, and Castells M. Rapid desensitization for hypersensitivity reactions to paclitaxel and docetaxel: a new standard protocol used in 77 successful treatments. Gynecol Oncol. 2005. 96(3): 824-9.
| Published | 19-11-2024 | |
| Fulltext |
|
|
| Language |
|
|
| Issue | Vol. 16 No. 7 (2024) | |
| Section | Original article | |
| DOI | 10.38103/jcmhch.16.7.3 | |
| Keywords | ung thư dạ dày tái phát di căn, paclitaxel Metastatic/recurrent gastric cancer, paclitaxel. |
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
Copyright (c) 2024 Journal of Clinical Medicine Hue Central Hospital